Bilstraat 106

3572 BJ, Utrecht, the Netherlands

info@virology-education.com

  • White Twitter Icon
  • White LinkedIn Icon
  • White Facebook Icon

Tel: +31 (0)30 230 7140
Fax: +31 (0)30 230 7148

© 2019 by Virology Education

Online &
Modulated
9 x 45
minutes
Letter of Completion

COURSE OVERVIEW

The complex landscape of oncology drug development is moving away from traditional dosing based on toxicity. As conventional strategies are becoming obsolete, it is vital for industry professionals to keep abreast of the novel approaches and modern toolsthat are becoming available in the development of anticancer drugs.

This advanced course will focus on new directions in drug development strategies and will include discussion of drug combinations, immunotherapy, and oral dosing regimens. Mathematical approaches will be introduced, including studies on pharmacodynamic biomarkers and pharmacometric modelling of efficacy and toxicity.

Any time 
At your
own place 
Meet the Instructors
Mark J. Ratain
MD
University of Chicago
USA
Lena Friberg
PharmD, PhD
University of Chicago
USA
Magnus Ingelman-Sundberg
PhD, BSc.Me
Karolinska Institutet
Sweden
Ruth Plummer
MD, PhD
Newcastle University 
United Kingdom
Jaap Verweij
MD, PhD
Erasmus Medical Centre
the Netherlands

Study takeaways

  • ​Define appropriate strategies for identification of the optimal therapeutic dose (and/or schedule) of a drug alone, or in combination with other drugs
     

  • Identify appropriate tools, such as biomarkers, pharmacometrics, and simulation, to address common problems in oncology drug development
     

  • ​Interpret clinical pharmacokinetic and pharmacodynamic results in the context of preclinical drug metabolism and pharmacokinetic data

The course is for

Oncologists  |  Clinical pharmacologists  |  HCPs involved in early clinical trials

 

Start FREE MODULE

 

 

or download the brochure

Benefit from this unique opportunity with the 
FREE MODULE